Abstract:Context • Crohn's disease and ulcerative colitis result in similar gastrointestinal (GI) symptoms, including pain, diarrhea, stools with mucus or blood, and ulceration or tissue damage within the alimentary canal. Gut microbiota play a crucial role in triggering, maintaining, and exacerbating inflammatory bowel disease (IBD). Probiotics might help to rebalance the gut flora in a positive way, shifting from pro- to anti-inflammatory. Objectives • The study intended to investigate the safety and use of probiotics and the biological effects of probiotic bacteria on IBD. Design • The research team performed a literature review. The team conducted a database search in April 2015 using Google Scholar and PubMed to find studies relevant to probiotics and their use in IBD. Only papers that were published in English were considered, and all available years in each database were searched. The initial search identified 38 published articles, for which the research team obtained full texts and independently read them in full to identify those papers suitable for inclusion in the review. Setting • The study took place in the main library of the University of Lahore (Islamabad, Pakistan). Results • Many strains of probiotics exist, but the most common strains available today are (1) the Bifidobacterium species, (2) Enterococcus faecium, (4) the Lactobacillus strains, (4) Saccharomyces boulardii, (5) the Bacillus species, and (6) Pediococcus, all used to produce beneficial health effects. These species showed their beneficial effects on the host using different mechanisms involving (1) production of proteins, quorum sensing signaling inhibitors, butyrate, immunoglobulin A, and short-chain fatty acids; (2) decreased production of tumor necrosis factor alpha and interleukin 8; (3) increased expression of mucin 2; and (4) increased upregulation of defensin. Conclusions • Studies on probiotics in animal models of IBD are promising, and clinical results in IBD patients are encouraging; however, the data are limited, and few studies are placebo controlled. Additional placebo-controlled, double-blind studies in IBD are required before recommendations can be offered for routine use of probiotics in IBD. Additional organisms may eventually be developed through genetic engineering. The current evidence also indicates that probiotic effects are strain specific; they do not act through the same mechanisms nor are all probiotics indicated for the same health conditions. More research is needed to determine what strains and at what dose probiotics become more useful as part of a clinical intervention.

Effects of proton pump inhibitors on inflammatory bowel disease: An updated review

Anti-cytokine Therapy and Small Molecule Agents for the Treatment of Inflammatory Bowel Disease

The Effect of Probiotics on Treatments in Patients Affected by Inflammatory Bowel Disease: A Systematic Review

Proton pump inhibitors may enhance the risk of digestive diseases by regulating intestinal microbiota

Proton pump inhibitor-induced gut dysbiosis and immunomodulation: current knowledge and potential restoration by probiotics

Proton Pump Inhibitors and Oral–Gut Microbiota: From Mechanism to Clinical Significance

Understanding the health risks and emerging concerns associated with the use of long-term proton pump inhibitors

The Relationship between Helicobacter pylori and Inflammatory Bowel Disease Based on Epidemiological Data: A Systematic Review and Meta-Analysis

A Review of the Novel Application and Potential Adverse Effects of Proton Pump Inhibitors

S1055 Does Starting PPIs Increase the Risk of Complications in IBD Patients on Biologics or Immunomodulators?: A Large Multicenter Cohort Study

The impact of proton pump inhibitors in liver diseases and the effects on the liver

The Positive Association between Proton Pump Inhibitors and Clostridium Difficile Infection

Role of prebiotics, probiotics, and synbiotics in management of inflammatory bowel disease: Current perspectives

Effects of Proton-Pump Inhibitors on Functional Dyspepsia: A Meta-analysis of Randomized Placebo-Controlled Trials

Elevated risk of adverse effects from foodborne contaminants and drugs in inflammatory bowel disease: a review

Clinical effects and gut microbiota changes of using probiotics, prebiotics or synbiotics in inflammatory bowel disease: a systematic review and meta-analysis

A review of the long-term use of proton pump inhibitors and risk of celiac disease in the context of HLA-DQ2 and HLA-DQ8 genetic predisposition

Proton pump inhibitor therapy and potential long-term harm

Research progress of probiotics and their protective strategy in the field of inflammatory bowel disease treatment: A review

Regulation of gut microbiota-bile acids axis by probiotics in inflammatory bowel disease

Probiotics and Their Use in Inflammatory Bowel Disease